Also known as Victoza · Saxenda · NN2211
The once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
Research refreshed
Liraglutide is a GLP-1 receptor agonist and the direct predecessor of semaglutide — the drug that proved the once-daily, acylated GLP-1 template before Novo Nordisk stretched it to once-weekly dosing. A fatty-acid chain on the GLP-1 backbone extends its half-life to about 13 hours, enough for daily injection. It was FDA-approved for type 2 diabetes (Victoza, 2010) and later, at higher dose, for chronic weight management (Saxenda, 2014).
Liraglutide is where the modern GLP-1 story really begins for daily therapy. It is a GLP-1(7-37) analog carrying a single amino-acid substitution and, crucially, a C16 palmitic-acid chain attached through a glutamate spacer to a lysine — an acylation that lets the peptide bind reversibly to albumin and resist rapid clearance. That change pushed GLP-1’s natural half-life of minutes out to roughly half a day, making once-daily injection practical.
Novo Nordisk brought it to market for type 2 diabetes as Victoza (2010) and then, at a higher dose, for chronic weight management as Saxenda (2014), backed by a cardiovascular-outcomes trial (LEADER) showing benefit in high-risk patients. Semaglutide is its direct successor — the same acylation strategy taken further to reach once-weekly dosing and larger weight effects — which makes liraglutide both a still-used medicine and the historical bridge to the drugs that followed it.
GLP-1 receptor agonism → glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction.
Behind every vial of Liraglutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Liraglutide, specifically, is brought into being.
On paper, Liraglutide is C172H265N43O51 — about 3,751.2 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Liraglutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Liraglutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Liraglutide proves itself: identity confirmed by mass spectrometry against its ~3,751.2 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Liraglutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Liraglutide is a GLP-1(7-37) analog carrying a C16 palmitoyl chain attached through a γ-glutamate spacer to a lysine, made by solid-phase synthesis. The single fatty-acid acylation is the defining step; over a 31-residue backbone, coupling efficiency and deletion-sequence removal set the purity.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Liraglutide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Liraglutide is a once-daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda); it is the direct predecessor of semaglutide.
Both are acylated GLP-1 agonists, but liraglutide is dosed once daily (~13-hour half-life) while semaglutide was engineered for once-weekly dosing and larger average weight loss.
Both are liraglutide. Victoza is approved for type 2 diabetes; Saxenda is the higher-dose version approved for chronic weight management.
Yes — for type 2 diabetes (Victoza) and chronic weight management (Saxenda). This page is a research and educational reference, not medical advice.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.